Literature DB >> 27571735

Seropositivity and epidemiology of human parechovirus types 1, 3, and 6 in Japan.

K Watanabe1, C Hirokawa2, T Tazawa3.   

Abstract

Human parechoviruses (HPeVs) mainly infect young children, causing mild gastrointestinal and respiratory diseases; however, HPeV type 3 (HPeV3) causes severe systemic diseases in young infants. To clarify the characteristics of HPeV infections from the aspects of seropositivity and epidemiology, we measured neutralizing antibody titres against HPeVs in individuals of in different age groups and isolated HPeVs from various clinical specimens in Niigata, Japan. The seropositivity to HPeV1, 3, and 6 was higher in older age group. HPeV1 and HPeV6 seropositivities were maintained in adults, whereas HPeV3 seropositivity was significantly lower in subjects aged >40 years (P < 0·001, P = 0·003). This result suggests that adults have increased susceptibility to HPeV3 as they lack neutralizing antibodies against HPeV3. Of the HPeV isolates, HPeV1 and HPeV6 frequently caused gastrointestinal symptoms. Moreover, gastroenteritis patients with HPeV1 and HPeV6 were mainly aged 6 months-1 year and ⩾2 years, respectively. In contrast, only HPeV3 was isolated from neonates and young infants with sepsis or sepsis-like syndrome, often with respiratory symptoms. These results suggest that clinical symptoms are clinically related to HPeV genotype and patients' age.

Entities:  

Keywords:  Epidemiology; human parechovirus; seroepidemiology

Year:  2016        PMID: 27571735      PMCID: PMC9150201          DOI: 10.1017/S0950268816001795

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  13 in total

1.  Detection of human parechovirus (HPeV)-3 in spinal fluid specimens from pediatric patients in the Chicago area.

Authors:  Beth Walters; Silvia Peñaranda; W Allan Nix; M Steven Oberste; Kathleen M Todd; Ben Z Katz; Xiaotian Zheng
Journal:  J Clin Virol       Date:  2011-08-03       Impact factor: 3.168

2.  Human parechovirus-3 infection in children, South Korea.

Authors:  Tae-Hee Han; Ju-Young Chung; Su Jeong You; Jeong-Lim Youn; Gyu-Hong Shim
Journal:  J Clin Virol       Date:  2013-06-22       Impact factor: 3.168

3.  Human parechovirus infections, Lyon, France, 2008-10: evidence for severe cases.

Authors:  Isabelle Schuffenecker; Etienne Javouhey; Yves Gillet; Béatrice Kugener; Geneviève Billaud; Daniel Floret; Bruno Lina; Florence Morfin
Journal:  J Clin Virol       Date:  2012-05-17       Impact factor: 3.168

4.  Human parechovirus infections and child myositis cases associated with genotype 3 in Osaka City, Japan, 2014.

Authors:  Seiji P Yamamoto; Atsushi Kaida; Takuto Naito; Taisuke Hosaka; Yusuke Miyazato; Shin-Ichi Sumimoto; Urara Kohdera; Atsushi Ono; Hideyuki Kubo; Nobuhiro Iritani
Journal:  J Med Microbiol       Date:  2015-01-11       Impact factor: 2.472

5.  Human parechovirus infections in Dutch children and the association between serotype and disease severity.

Authors:  K S M Benschop; J Schinkel; R P Minnaar; D Pajkrt; L Spanjerberg; H C Kraakman; B Berkhout; H L Zaaijer; M G H M Beld; K C Wolthers
Journal:  Clin Infect Dis       Date:  2005-12-12       Impact factor: 9.079

6.  Human parechovirus type 3 central nervous system infections in Israeli infants.

Authors:  Nesrin Ghanem-Zoubi; Maayan Shiner; Lester M Shulman; Danit Sofer; Dana Wolf; Eytan Marva; Zipi Kra-Oz; Yael Shachor-Meyouhas; Dina Averbuch; Avital Bechor-Fellner; Galia Barkai; Amalia Kinarty; Vladimir Gershstein; Moshe Ephros
Journal:  J Clin Virol       Date:  2013-06-28       Impact factor: 3.168

7.  Epidemic myalgia and myositis associated with human parechovirus type 3 infections occur not only in adults but also in children: findings in Yamagata, Japan, 2014.

Authors:  K Mizuta; T Yamakawa; K Kurokawa; S Chikaoka; Y Shimizu; T Itagaki; F Katsushima; Y Katsushima; S Ito; Y Aoki; Y Matoba; S Tanaka; K Yahagi
Journal:  Epidemiol Infect       Date:  2015-11-20       Impact factor: 2.451

8.  Dermatologic manifestations of human parechovirus type 3 infection in neonates and infants.

Authors:  Kensuke Shoji; Hisako Komuro; Ippei Miyata; Isao Miyairi; Akihiko Saitoh
Journal:  Pediatr Infect Dis J       Date:  2013-03       Impact factor: 2.129

9.  Parechovirus Genotype 3 Outbreak among Infants, New South Wales, Australia, 2013-2014.

Authors:  Germaine Cumming; Ameneh Khatami; Brendan J McMullan; Jennie Musto; Kit Leung; Oanh Nguyen; Mark J Ferson; Georgina Papadakis; Vicky Sheppeard
Journal:  Emerg Infect Dis       Date:  2015-07       Impact factor: 6.883

10.  Human parechovirus infections in patients admitted to hospital in Northern Italy, 2008-2010.

Authors:  Antonio Piralla; Milena Furione; Francesca Rovida; Antonietta Marchi; Mauro Stronati; Giuseppe Gerna; Fausto Baldanti
Journal:  J Med Virol       Date:  2012-04       Impact factor: 2.327

View more
  8 in total

Review 1.  Human Parechovirus: an Increasingly Recognized Cause of Sepsis-Like Illness in Young Infants.

Authors:  Laudi Olijve; Lance Jennings; Tony Walls
Journal:  Clin Microbiol Rev       Date:  2017-11-15       Impact factor: 26.132

2.  Strain-dependent neutralization reveals antigenic variation of human parechovirus 3.

Authors:  Eveliina Karelehto; Sabine van der Sanden; James A Geraets; Aušra Domanska; Lonneke van der Linden; Dionne Hoogendoorn; Gerrit Koen; Hetty van Eijk; Shabih Shakeel; Tim Beaumont; Menno de Jong; Dasja Pajkrt; Sarah J Butcher; Katja C Wolthers
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

3.  Advances on Antiviral Activity of Morus spp. Plant Extracts: Human Coronavirus and Virus-Related Respiratory Tract Infections in the Spotlight.

Authors:  Inès Thabti; Quentin Albert; Stéphanie Philippot; François Dupire; Brenda Westerhuis; Stéphane Fontanay; Arnaud Risler; Thomas Kassab; Walid Elfalleh; Ali Aferchichi; Mihayl Varbanov
Journal:  Molecules       Date:  2020-04-18       Impact factor: 4.411

4.  Seroepidemiology of Parechovirus A3 Neutralizing Antibodies, Australia, the Netherlands, and United States.

Authors:  Eveliina Karelehto; Lieke Brouwer; Kimberley Benschop; Jen Kok; Kerri Basile; Brendan McMullan; William Rawlinson; Julian Druce; Suellen Nicholson; Rangaraj Selvarangan; Christopher Harrison; Kamani Lankachandra; Hetty van Eijk; Gerrit Koen; Menno de Jong; Dasja Pajkrt; Katja C Wolthers
Journal:  Emerg Infect Dis       Date:  2019-01       Impact factor: 6.883

5.  Evolutionary analysis of human parechovirus type 3 and clinical outcomes of infection during the 2017-18 Australian epidemic.

Authors:  Anthony Chamings; Julian Druce; Leon Caly; Yano Yoga; Philip N Britton; Kristine K Macartney; Soren Alexandersen
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

Review 6.  Parechovirus A Pathogenesis and the Enigma of Genotype A-3.

Authors:  Adithya Sridhar; Eveliina Karelehto; Lieke Brouwer; Dasja Pajkrt; Katja C Wolthers
Journal:  Viruses       Date:  2019-11-14       Impact factor: 5.048

7.  Characterization of Pathogenesis and Inflammatory Responses to Experimental Parechovirus Encephalitis.

Authors:  Ming-Wei Jan; Hong-Lin Su; Tsung-Hsien Chang; Kuen-Jer Tsai
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

8.  Human Parechovirus 1, 3 and 4 Neutralizing Antibodies in Dutch Mothers and Infants and Their Role in Protection Against Disease.

Authors:  Eveliina Karelehto; Joanne G Wildenbeest; Kimberley S M Benschop; Gerrit Koen; Sjoerd Rebers; Saskia Bouma-de Jongh; Brenda M Westerhuis; Menno D de Jong; Dasja Pajkrt; Katja C Wolthers
Journal:  Pediatr Infect Dis J       Date:  2018-12       Impact factor: 2.129

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.